A carregar...

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

SUMMARY: Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate the cost-effectiveness of denosumab in a Swedish setting, also accounting for poor adherence to treatment. Denosumab is cost-effective, particularly for patients at high risk of fracture and lo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Osteoporos Int
Main Authors: Jönsson, B., Ström, O., Eisman, J. A., Papaioannou, A., Siris, E. S., Tosteson, A., Kanis, J. A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104532/
https://ncbi.nlm.nih.gov/pubmed/20936401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-010-1424-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!